All News

New Drug Combo Boasts Improved Outcomes, Fewer Side Effects in Melanoma

January 7th 2022

Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.

Some Allergy Medications May Positively Influence Immunotherapy Responses in Cancer, But Is Only ‘A Tip of the Iceberg’

January 6th 2022

Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.

Although Physicians Prefer Colonoscopy, Many Are Implementing Shared Decision-Making With Patients in Colon Cancer Screening

January 6th 2022

“It is frequently said that the best screening test is the one patients are willing to complete,” a researcher said. However, some experts note that colonoscopies are the gold standard for detecting and confirming colorectal cancer.

How I Learned to Live After Learning How to Die From Cancer

January 6th 2022

A pancreatic cancer survivor explains how he learned to live after cancer and reflects on lessons learned from the book, “Tuesdays with Morrie.”

Expert Explores the Relationship Between Down Syndrome and Leukemia

January 6th 2022

In this episode of the “Cancer Horizons” podcast, an expert unpacks cancer risks for individuals with Down syndrome and analyzes the results of a recent study about mortality risks for childhood survivors later in life.

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

January 6th 2022

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

Trial Underway to Assess Efficacy of Novel Radiopharmaceutical Drug in Neuroendocrine Tumors

January 5th 2022

The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

January 5th 2022

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

Regardless of How Many New Year’s Resolutions People Make, A Patient With Cancer Advises Advocating for Oneself

January 5th 2022

After a challenging year due to COVID-19 and rising blood test numbers, a woman living with ovarian cancer shares on what she’s learned and how she’s approaching 2022.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

Families and Caregivers Must 'Juggle' Between Risks and Benefits of Treating Children with Skin Cancer

January 5th 2022

The recent FDA approval of Keytruda, an immunotherapy monoclonal antibody drug, for children with melanoma is an exciting development, according to an expert. But there is potential for certain side effects that children and their family should consider before undergoing treatment.

2021’s Most-Read Childhood Cancer Stories

January 4th 2022

From long-term effects of pediatric cancer to a survivor fulfilling her dream of being an astronaut, CURE® looked back on its most-read childhood cancer stories of the year.

Optimism Versus Realism When It Comes to Cancer

January 4th 2022

A sister of a woman with cancer writes about how the idea of recurrence faded to the back of her mind, but now she must be realistic about the future.

FDA Grants Speedy Review for Novel NSCLC Therapy

January 4th 2022

The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.

The Most-Read Myeloma Stories of 2021

January 4th 2022

From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

January 3rd 2022

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

Mortality Risk Later in Life May Be Increased in Childhood Leukemia Survivors With Down Syndrome

January 3rd 2022

Patients with Down syndrome have an increased risk for leukemia during childhood, and toxicities related to treatment may be more common in this patient population.

My Plan to Help Fellow Cancer Survivors in 2022

January 3rd 2022

A cancer survivor pens a poem about his New Year’s resolutions to help other survivors through obstacles in 2022.

Survival With Immunotherapy in Common Brain Tumor Subtype May Be Predicted by a Biomarker

January 3rd 2022

Patients with a common brain tumor subtype that expresses ERK1/2 activation may obtain a greater survival benefit with PD-1 immunotherapy, although research needs to confirm whether this can be observed in all patients.

A Deep Dedication to Improving Outcomes for Patients With Lung Cancer

January 3rd 2022

An oncologist from Fox Chase Cancer Center in Philadelphia explains the early career mentorship that inspired his successful lung cancer career.

Breaking the Stigma: Anyone Can Get Lung Cancer

January 2nd 2022

Not having known much about lung cancer, a woman describes her shock at receiving a diagnosis despite being a non-smoker.

The Top 5 Cancer-Related Podcast Episodes of 2021

January 1st 2022

CURE® compiled its top 5 most-listened-to podcast episodes from this year, featuring cancer survivor stories, caregivers and experts.

Innovating the Future of Lung Cancer Care

January 1st 2022

A lung cancer doctor explains how he got lucky to fill in a role in the lung cancer space, and his career and passion took off from there.

The Lung Cancer Advocate Who Is a Friend to All

December 31st 2021

A woman who has worked with Upal Basu Roy in the lung cancer space for many years explains why he is a lung cancer hero to everyone he has worked with, due to his dedication and empathy.

What’s Most Commonly Misunderstood About My Cancer Experience

December 31st 2021

A young adult cancer survivor describes the ways people typically misunderstand his cancer experiences.

Welireg May Promote Strong Clinical Activity in VHL-Associated Kidney Cancer With Mild Side Effects

December 30th 2021

As the standard treatment for patients with renal cell carcinoma, the most common type of kidney cancer, related to VHL disease is often surgical procedures, the use of Welireg may reduce surgical burden in patients.

It Takes a ‘Huge Clinic Village’ to Create a Dream Cancer Care Team

December 30th 2021

From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.

How Long Should a Cancer Survivor Keep Seeing Their Oncologist?

December 30th 2021

A person with cancer may naturally assume an oncologist will follow them throughout the course of treatment, but when that person survives for many years, things can rapidly change.

Rock Star Lung Cancer Supporter and Advocate

December 30th 2021

A lung cancer survivor describes a passionate advocate who has changed the world of many patients.

Body Composition May Be a Better Predictor of Chemotoxicities in Children With Lymphoma or a Type of Sarcoma Than BMI

December 29th 2021

Children with low skeletal muscle density were more likely to have hematologic toxicities from chemotherapy, but more research is needed to determine whether this measure is an accurate predictor of chemotoxicities in lymphoma.